News

Earlier in March, the company received approval of an abbreviated new drug application (ANDA) for the product from the US Food and Drug Administration (FDA) The company’s product

As part of the deal, both the firms will jointly work to develop an adjuvanted non-alum based rPA vaccine. The deal provides PharmAthene exclusive worldwide rights to use

As part of its collaboration agreement with the French firm, Cellectis is eligible for an undisclosed payment. Signed in February 2014, the collaboration is focused on research, development

Each year, manufacturers of influenza vaccine must receive approval from the FDA for changes they make to their vaccines so that the vaccines protect against the new strains

Arrowhead’s ARC-AAT is being investigated for the treatment of liver disease associated with the rare genetic disorder alpha-1 antitrypsin deficiency (AATD). The Phase I trial is currently enrolling

As part of the collaboration, both the parties will identify and co-fund translational research projects with leading academic medical centers within the CTI network. JMF noted that the

Non-24 is a chronic, circadian rhythm disorder which results from the misalignment of the endogenous master body clock to the 24-hour day, disrupting the sleep-wake cycle. Hetlioz is

DX-2930 is currently being developed by the company as a subcutaneous injection for prevention of HAE attacks. The company noted that uncontrolled pKal activity leads to excessive generation

As part of this deal, the university is looking forward to advancing new formulations of CBD to meet serious medical conditions where non-psychotropic cannabinoids can play a significant